Coronavirus company news summary – EU invests €75m in CureVac infectious disease programmes – WHO finds many countries are at risk of HIV drug shortages due to Covid-19 pandemic

Allie Nawrat 7 July 2020 (Last Updated July 7th, 2020 08:49)

7 July 2020 

Regeneron Pharmaceuticals has started Phase III clinical trials of its double antibody cocktail, REGN-COV2, for the treatment and prevention of Covid-19. The company is initially conducting, in partnership with the National Institute of Allergy and Infectious Diseases (NIAID), a Phase III trial to assess REGN-COV2 for prevention of infection in people with close exposure to a Covid-19 patient.

The European Union's European Investment Bank (EIB) and European Commission have provided German company CureVac with €75m in fundin to support the development and expand the manufacturing of infectious disease vaccines, including its Covid-19 vaccine candidate. The financing will be available in three €25m tranches at the completion of pre-defined milestones.

Mylan has secured approval from the Drug Controller General of India (DCGI) for restricted emergency use of 100mg/vial of remdesivir for the treatment of Covid-19 patients. The approval is for suspected or laboratory confirmed cases of Covid-19 in adults and children hospitalised with severe disease.

According to a World Health Organization (WHO) survey, 73 countries responded that they are at risk of running out of HIV drugs due to disruptions to supply lines and other challenges caused by the Covid-19 pandemic. Of these 73 countries, 24 are already experiencing critically low supplies of the drugs, added WHO.

Immune Regulation has signed a teaming agreement with DynPort Vaccine to assess ILR201104 as a potential treatment for acute respiratory distress syndrome (ARDS) caused by Covid-19. The partners intend to conduct clinical trials of the drug candidate in Covid-19 patients in the US.